OptimizeRx
OPRX
142 hedge funds and large institutions have $760M invested in OptimizeRx in 2021 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 45 increasing their positions, 40 reducing their positions, and 18 closing their positions.
117% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 18
114% more call options, than puts
Call options by funds: $55.2M | Put options by funds: $25.8M
34% more capital invested
Capital invested by funds: $567M → $760M (+$192M)
17% more funds holding
Funds holding: 121 → 142 (+21)
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
13% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 40
2.18% more ownership
Funds ownership: 68.96% → 71.14% (+2.2%)
Top Buyers
Top Sellers
| 1 |
MS
Maven Securities
St Helier,
Jersey
|
-$5.73M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$5.11M |
| 3 |
Two Sigma Investments
New York
|
-$3.84M |
| 4 |
GIPM
G2 Investment Partners Management
New York
|
-$3.02M |
| 5 |
NCGI
Next Century Growth Investors
Plymouth,
Minnesota
|
-$2.11M |
OPRX Hedge Fund Activity: Q2 2021 in Review
142 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in OptimizeRx (OPRX) for Q2 2021, worth a combined $760M — up 34% from $567M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new OPRX positions and 18 closed out — a net gain of 21 holders — while 45 added to existing stakes and 40 trimmed.
The largest buyer was Prospect Capital Advisors, opening a new position worth an estimated $15.6M. The largest seller was Maven Securities, cutting an estimated $5.73M.
- 142 institutional investors held OptimizeRx (OPRX) as of Q2 2021, up from 121 in Q1 2021.
- Funds reported $760M of OptimizeRx stock for Q2 2021, up 34% quarter-over-quarter.
- 39 funds opened new OptimizeRx positions in Q2 2021 and 18 closed out, a net change of +21 holders.
- The largest OptimizeRx buyer in Q2 2021 was Prospect Capital Advisors, an estimated $15.6M added.
- The largest OptimizeRx seller in Q2 2021 was Maven Securities, an estimated $5.73M sold.
Based on aggregated 13F filings for Q2 2021.